Video Experimental Relacionado
Updated: Aug 7, 2026
08:28
Experimental Metastasis Assay
Published on: August 24, 2010
Inhibidores de la metaloproteinasa de matriz y cáncer: ensayos y tribulaciones
Lisa M Coussens1, Barbara Fingleton, Lynn M Matrisian
1Department of Pathology and Cancer Research Institute, University of California, 2340 Sutter Street, San Francisco, CA 94143, USA.
Science (New York, N.Y.)
|March 30, 2002
Resumen
Los inhibidores de la metaloproteinasa de matriz (IMP) son prometedores para el tratamiento del cáncer debido a los MMP.
Área de la Ciencia:
- Oncología Oncología.
- La bioquímica es la bioquímica.
Sus antecedentes:
- Las metaloproteinasas de matriz (MMP) se regulan en los tejidos malignos y degradan la matriz extracelular.
- Los MMP se han considerado objetivos terapéuticos prometedores para el tratamiento del cáncer.
- Los inhibidores sintéticos de la metaloproteinasa (IMP) se desarrollaron sobre la base de datos preclínicos convincentes.
Objetivo del estudio:
- Revisar los estudios que conducen a ensayos clínicos de IMP.
- Para discutir el diseño del ensayo MPI y los resultados a la luz de la nueva información MMP.
- Para extraer lecciones para futuros estudios de MPI y el desarrollo de fármacos contra el cáncer.
Principales métodos:
- Revisión de estudios preclínicos y ensayos clínicos en humanos de IBM.
- Análisis de nueva información sobre la fuente celular, los sustratos y la acción de los MMP durante la progresión tumoral.
Principales resultados:
- Los estudios preclínicos mostraron una eficacia convincente de la supresión de MMP.
- Los ensayos clínicos en humanos con IMP han arrojado resultados decepcionantes.
- Nuevos datos revelan complejidades en las funciones de los MMP en diferentes etapas de la progresión tumoral.
Conclusiones:
- El fracaso clínico de los IMP pone de relieve una brecha entre la promesa preclínica y la realidad terapéutica.
- Comprender las diversas funciones de los MMP es crucial para una terapia eficaz contra el cáncer.
- Las lecciones de la experiencia del MPI pueden guiar el futuro desarrollo de fármacos contra el cáncer.
Videos de Conceptos Relacionados
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...